[Expert consensus on the long-term management of gonadotropin-releasing hormone agonists in premenopausal patients with hormone receptor-positive breast cancer (2026 edition)].

Authors

Committee of Breast Cancer Society of Chinese Anti-Cancer Association, Breast Cancer Expert Committee of National Cancer Quality Control Center, Committee of Fertility Protection of Chinese Anti-Cancer Association

Published in

Zhonghua zhong liu za zhi [Chinese journal of oncology]. Volume 48. Issue 7. Pages 851-865. Jul 23, 2026.

Abstract

Compared with postmenopausal patients, premenopausal patients with hormone receptor-positive (HR⁺) breast cancer generally exhibit higher tumor heterogeneity, greater invasiveness and a poorer prognosis, with a 5-year postoperative recurrence rate of 20%-30%. Endocrine therapy based on ovarian function suppression (OFS) is a key strategy to reduce the risk of recurrence, and gonadotropin-releasing hormone agonists (GnRHa) are commonly used agents for OFS in clinical practice. GnRHa combined with endocrine therapy has become the standard treatment regimen for intermediate- and high-risk premenopausal patients with HR⁺ breast cancer. The recommended treatment duration is 5 years, and extended treatment may be considered in selected high-risk patients. However, long-term GnRHa use (2-5 years or >5 years) may lead to decreased treatment adherence or increased adverse events, thereby potentially affecting patient prognosis. Furthermore, there is still a lack of standardization regarding the appropriate patient population for GnRHa use beyond 5 years, long-term management strategies, and drug switching approaches. To address these issues, the Committee of Breast Cancer Society of Chinese Anti-Cancer Association and other organizations convened a panel of experts to develop this consensus based on domestic and international evidence-based medical evidence and clinical practice in China, following the Delphi method. This consensus aims to standardize the long-term application and management of GnRHa, provide a reference for clinicians, help patients complete the planned treatment courses, and ultimately improve patients' quality of life and long-term prognosis.

PMID:
42477924
Bibliographic data and abstract were imported from PubMed on 21 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.